<SEC-DOCUMENT>0001193125-20-210786.txt : 20200805
<SEC-HEADER>0001193125-20-210786.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805171457
ACCESSION NUMBER:		0001193125-20-210786
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235324
		FILM NUMBER:		201078590

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d80466d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">As Filed Pursuant to Rule 424(b)(5) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Registration No.: 333-235324 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title&nbsp;of&nbsp;Securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>to&nbsp;be&nbsp;Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Offering&nbsp;Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registration&nbsp;Fee(1)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$32,450.00</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This &#147;Calculation of
Registration Fee&#148; table shall be deemed to update the &#147;Calculation of Registration Fee&#148; table in the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-235324)</FONT> in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(to
Prospectus dated December&nbsp;2, 2019) </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80466g58w64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>ARROWHEAD PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Up to $250,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have entered into an Open Market Sale Agreement<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> (the &#147;Sales Agreement&#148;), with Jefferies LLC
(&#147;Jefferies&#148;), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an
aggregate offering price of up to $250,000,000 from time to time through Jefferies, acting as our sales agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on The Nasdaq Global
Select Market (&#147;Nasdaq&#148;) under the symbol &#147;ARWR.&#148; On August 4, 2020, the last reported sale price of our common stock on Nasdaq was $44.12 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4)
promulgated under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Jefferies is not required to sell any specific amount of our common stock, but will act as our sales agent and use commercially reasonable efforts to sell on
our behalf all of the shares of common stock requested to be sold by us, consistent with its normal sales and trading practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Jefferies will receive from us a commission of up to 3.0% of the gross proceeds of any shares of common stock sold through it under the
Sales Agreement. In connection with the sale of our common stock on our behalf, Jefferies will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting
commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>An investment in our securities involves a high degree of risk. Please read &#147;<A HREF="#suptoc80466_3">Risk Factors</A>&#148; on page <FONT
STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement before investing in our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus supplement is August 5, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prospectus&nbsp;Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_4">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_7">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_8">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_10">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc80466_11">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prospectus </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_2">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_3">About the Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_6">Description of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_7">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_8">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_11">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx80466_12">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before buying any of the common stock that we are offering, we
urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of
Certain Information by Reference&#148; in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates
information contained in the accompanying prospectus and the documents incorporated by reference herein or therein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are
referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this
prospectus supplement that was filed with the Securities and Exchange Commission (the &#147;SEC&#148;), before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any
statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into this prospectus supplement&#151;the statement in the document having the later
date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We further note that the representations, warranties and covenants made by us in any agreement that is filed as
an exhibit to any document that is incorporated by reference herein or in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties
to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not, and Jefferies has not, authorized anyone to provide you
with any information other than the information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, and in any free writing prospectuses that we have
authorized for use in connection with this offering. We take no responsibility for, and can provide no assurances as to the reliability of, any information that is in addition to or different from that contained or incorporated by reference in this
prospectus supplement and the accompanying prospectus. We are not, and Jefferies is not, making an offer to sell or seeking an offer to buy our common stock under this prospectus in any jurisdiction where the offer or sale is not permitted. Persons
outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside the United States.
Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or
solicitation. You should not assume that the information contained in this prospectus or any free writing prospectus is accurate as of any date other than the date on the front cover of those documents, or that the information contained in any
document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. Our business, financial condition, results
of operations and prospects may have changed since those dates. It is important for you to read and consider all information contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and
therein, and any free writing prospectus prepared by or on behalf of us that we may authorize for use in connection with this offering, in their entirety, before making an investment decision. You should also read and consider the information in the
documents to which we have referred you in the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and in the accompanying prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In this prospectus supplement, &#147;Arrowhead,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; and similar terms refer to Arrowhead
Pharmaceuticals, Inc. and its subsidiaries, unless the context indicates otherwise. References to our &#147;common stock&#148; refer to the common stock, par value $0.001 per share, of Arrowhead Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All references in this prospectus supplement to our financial statements include, unless the context indicates
otherwise, the related notes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The industry and market data and other statistical information contained in this prospectus supplement, the accompanying prospectus
and the documents we incorporate by reference herein and therein are based on management&#146;s own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in each
case, are believed by management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience,
trademarks and trade names referred to in this prospectus supplement and the accompanying prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM
symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146;
trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights certain information about this offering and selected information contained elsewhere in or incorporated by reference into this prospectus
supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our shares of common stock. You should carefully read this entire
prospectus supplement and accompanying prospectus, including the information incorporated herein and therein, including the &#147;Risk Factors&#148; section contained in this prospectus supplement and the other documents incorporated by reference
into this prospectus supplement. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arrowhead
Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism
to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#146;s
RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#146;s pipeline includes <FONT STYLE="white-space:nowrap">ARO-AAT</FONT> for liver disease associated with <FONT STYLE="white-space:nowrap">alpha-1</FONT>
antitrypsin deficiency (AATD), <FONT STYLE="white-space:nowrap">ARO-APOC3</FONT> for hypertriglyceridemia, <FONT STYLE="white-space:nowrap">ARO-ANG3</FONT> for dyslipidemia, <FONT STYLE="white-space:nowrap">ARO-HSD</FONT> for liver disease, ARO-ENaC
for cystic fibrosis, <FONT STYLE="white-space:nowrap">ARO-HIF2</FONT> for renal cell carcinoma, <FONT STYLE="white-space:nowrap">ARO-LUNG2</FONT> as a candidate to treat chronic obstructive pulmonary disorder (COPD) and <FONT
STYLE="white-space:nowrap">ARO-COV</FONT> for treatment for the current novel coronavirus that causes <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other possible future pulmonary-borne pathogens.
<FONT STYLE="white-space:nowrap">ARO-JNJ1</FONT> is being developed for an undisclosed liver-expressed target under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#147;Janssen&#148;). <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> <FONT
STYLE="white-space:nowrap">(JNJ-3989)</FONT> for chronic hepatitis B virus was <FONT STYLE="white-space:nowrap">out-licensed</FONT> to Janssen in October 2018. <FONT STYLE="white-space:nowrap">ARO-LPA</FONT> (AMG 890) for cardiovascular disease was <FONT
STYLE="white-space:nowrap">out-licensed</FONT> to Amgen Inc. (&#147;Amgen&#148;) in 2016. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arrowhead operates a lab facility in Madison, Wisconsin, where the
Company&#146;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#146;s principal executive offices are located in Pasadena, California. In March 2020, the Company entered into a sublease for
additional research and development facility space in San Diego, California. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During fiscal year 2020, the Company has continued to develop its pipeline and
partnered candidates. The Company has begun dosing in an adaptive design phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registration study of <FONT STYLE="white-space:nowrap">ARO-AAT.</FONT> The Company also began dosing
in its <FONT STYLE="white-space:nowrap">ARO-AAT</FONT> 2002 study, a pilot open-label, multi-dose Phase 2 study to assess changes in novel histological activity scale in response to <FONT STYLE="white-space:nowrap">ARO-AAT</FONT> over time in
patients with <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency associated liver disease. In addition, the Company also dosed the first patients in AROHSD1001, a Phase <SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB
STYLE="vertical-align:bottom">2</SUB> clinical study of <FONT STYLE="white-space:nowrap">ARO-HSD,</FONT> the Company&#146;s investigational RNA interference therapeutic being developed as a treatment for patients with alcohol related and nonalcohol
related liver diseases, such as nonalcoholic steatohepatitis (NASH). The Company also presented new clinical data on its two cardiometabolic candidates, <FONT STYLE="white-space:nowrap">ARO-APOC3</FONT> and
<FONT STYLE="white-space:nowrap">ARO-ANG3,</FONT> in two late-breaking oral presentations at the American Heart Association Scientific Sessions 2019. In addition, the Company filed an investigational new drug (&#147;IND&#148;) application to begin a
phase 1b study of <FONT STYLE="white-space:nowrap">ARO-HIF2</FONT> and filed a clinical trials application (&#147;CTA&#148;) to begin a phase 1 study of ARO-ENaC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s partnered candidates under its collaboration agreements with Janssen and Amgen also continue to progress. Janssen began dosing patients in a phase 2b
triple combination study called <FONT STYLE="white-space:nowrap">REEF-1,</FONT> designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a $25&nbsp;million milestone
payment under the License Agreement (&#147;Janssen License Agreement&#148;). Janssen has also nominated the first of 3 potential candidates under the Research Collaboration and Option Agreement (&#147;Janssen Collaboration Agreement&#148;), <FONT
STYLE="white-space:nowrap">ARO-JNJ1,</FONT> and the Company is currently performing discovery, optimization and preclinical research and development for this candidate. Under the terms of the Janssen agreements taken together, the Company has
received $175&nbsp;million as an upfront payment, $75&nbsp;million in the form of an equity investment by Johnson&nbsp;&amp; Johnson Innovation JJDC, Inc. in Arrowhead common stock, and two $25&nbsp;million milestone payments and may receive up to
$1.6&nbsp;billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9&nbsp;billion in development and sales milestone payments </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for the three additional targets covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties up to mid teens under the Janssen License Agreement
and up to low teens under the Janssen Collaboration Agreement on product sales. The Company&#146;s collaboration agreement with Amgen for AMG 890 <FONT STYLE="white-space:nowrap">(ARO-LPA),</FONT> (the &#147;Second Collaboration and License
Agreement&#148; or &#147;AMG 890 <FONT STYLE="white-space:nowrap">(ARO-LPA)</FONT> Agreement&#148;), continues to progress. The Company has received $35&nbsp;million in upfront payments, $21.5&nbsp;million in the form of an equity investment by
Amgen in the Company&#146;s common stock, and a $10&nbsp;million milestone payment, and may receive up to $420&nbsp;million in development, regulatory and sales milestone payments. The Company is eligible to receive up to low double-digit royalties
for sales of products under the AMG 890 <FONT STYLE="white-space:nowrap">(ARO-LPA)</FONT> Agreement. In July 2020, Amgen initiated a Phase 2 clinical study, which will result in a $20&nbsp;million milestone payment to the Company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is actively monitoring the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The financial results for the three and nine months ended
June&nbsp;30, 2020 were not significantly impacted by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The Company temporarily paused enrollment in its two <FONT STYLE="white-space:nowrap">ARO-AAT</FONT> studies, SEQUOIA and the <FONT
STYLE="white-space:nowrap">ARO-AAT</FONT> 2002 study, but resumed the process of screening and enrolling patients during the three months ended June&nbsp;30, 2020. During the pause in enrollment, patients already enrolled in these studies continued
to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#146;s earlier stage programs, but the Company does not expect a material impact to any program&#146;s anticipated
timelines. Several of the Company&#146;s and other clinical candidates are in the <FONT STYLE="white-space:nowrap">start-up</FONT> stage <FONT STYLE="white-space:nowrap">(ARO-HSD,</FONT> <FONT STYLE="white-space:nowrap">ARO-HIF2</FONT> and
ARO-ENaC), during which significant clinical costs will continue to be incurred. Additionally, the Company&#146;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters
in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures including work from home policies. However, the Company cannot predict the impact of the progression of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> will have on future financial results due to a variety of factors including the ability of the Company&#146;s clinical sites to continue to enroll subjects, the ability of the Company&#146;s suppliers
to continue to operate, the continued good health and safety of the Company&#146;s employees, and ultimately the length of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our executive offices are located at 177 E. Colorado
Blvd., Suite 700, Pasadena CA 91105, and our telephone number is (626) <FONT STYLE="white-space:nowrap">304-3400.</FONT> Additional information regarding our company, including our audited financial statements and descriptions of our business, is
contained in the documents incorporated by reference in this prospectus. See &#147;Incorporation of Certain Information by Reference&#148; and &#147;Where You Can Find More Information&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-15</FONT>
of this prospectus supplement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $250,000,000. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD>Up to 107,917,236 shares of common stock (as more fully described in the notes following this table), assuming sales of 5,666,364 shares of our common stock in this offering at an offering price of $44.12 per share, which was the last reported
sale price of our common stock on Nasdaq on August&nbsp;4, 2020. The actual number of shares issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Plan of Distribution </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, Jefferies. See the section entitled &#147;Plan of Distribution&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-12</FONT> of this prospectus
supplement. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also
be used for the acquisition of businesses, products and technologies or for other strategic purposes. See the section titled &#147;Use of Proceeds&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk Factors </P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and in the documents incorporated by reference herein for a discussion of factors you should consider carefully before
investing in our common stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Nasdaq symbol </P></TD>
<TD>&#147;ARWR&#148; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 102,250,872 shares of our common
stock outstanding as of June&nbsp;30, 2020, and excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,529,564 shares of our common stock subject to options outstanding as of June 30, 2020 having a weighted average exercise
price of $15.71 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">3,327,075 restricted stock units granted and outstanding as of June 30, 2020 under our 2013 Equity Incentive Plan and
issued as inducement grants to new employees outside of our equity compensation plans. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should carefully consider the
risk factors described below and the risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports in Form <FONT
STYLE="white-space:nowrap">10-Qs</FONT> and our other filings with the SEC incorporated by reference in this prospectus supplement, together with all of the other information contained in this prospectus supplement. Additional risks and
uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. Our business, financial condition and results of operations could be materially and adversely affected as a result of these risks. This
could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will have broad discretion in the use of the net proceeds from this offering and, despite our efforts, we may use the net proceeds in a manner that does not
increase the value of your investment. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to use the net proceeds from this offering for general corporate purposes, including working
capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of businesses, products and technologies or for other strategic purposes.
However, we have not determined the specific allocation of the net proceeds among these potential uses. Our management will have broad discretion over the use and investment of the net proceeds from this offering, and, accordingly, investors in this
offering will need to rely upon the judgment of our management with respect to the use of proceeds, with only limited information concerning our specific intentions. These proceeds could be applied in ways that do not improve our operating results
or increase the value of your investment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may experience immediate and substantial dilution in the net tangible book value per share of the common stock
you purchase in the offering. In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to you. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering price per share in this offering may exceed the pro forma net tangible book value per share of our common stock outstanding as of August 3, 2020. Assuming
that an aggregate of 5,666,364 shares of our common stock are sold at a price of $44.12 per share, the last reported sale price of our common stock on Nasdaq on August&nbsp;4, 2020, for aggregate gross proceeds of approximately $250,000,000, and
after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $37.44&nbsp;per share, representing the difference between our pro forma as adjusted net tangible book value per share as
of June&nbsp;30, 2020 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options could result in further dilution of your investment. See the section titled &#147;Dilution&#148; below for a more
detailed illustration of the dilution you may incur if you participate in this offering. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common stock or securities convertible or
exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sales of our common stock in this offering, or the perception that such sales may occur, could cause the market price of our common stock to fall. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may issue and sell shares of our common stock for aggregate gross proceeds of up to $250&nbsp;million from time to time in connection with this offering. The actual
number of shares of common stock that may be issued and sold in this offering, as well as the timing of any such sales, will depend on a number of factors, including, among others, the prices at which any shares are actually sold this offering
(which may be influenced by market conditions, the trading price of our common stock and other factors) and our determinations as to the appropriate timing, sources and amounts of funding we need. The issuance and sale from time to time of these new
shares of common stock, or the mere fact that we are able to issue and sell these shares in this offering, could cause the market price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future,
stockholders must rely on appreciation of the value of our common stock for any return on their investment. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not distribute cash to our stockholders
unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, we
expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It is
not possible to predict the actual number of shares of common stock we will sell under the Sales Agreement, or the gross proceeds resulting from those sales. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Jefferies at any time
throughout the term of the Sales Agreement. The number of shares that are sold through Jefferies after delivering a placement notice will fluctuate based on a number of factors, including the market price of our shares during the sales period, the
limits we set with Jefferies in any applicable placement notice, and the demand for our shares during the sales period. Because the price per share of each share sold will fluctuate during this offering, it is not currently possible to predict the
number of shares that will be sold or the gross proceeds to be raised in connection with those sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain or incorporate forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). These forward-looking statements reflect management&#146;s beliefs and
assumptions. In addition, these forward-looking statements reflect management&#146;s current views with respect to future events or our financial performance, and involve certain known and unknown risks, uncertainties and other factors, including
those identified below, which may cause our or our industry&#146;s actual or future results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statements or from historical
results. We intend the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. Forward-looking statements
include information concerning our possible or assumed future results of operations and statements preceded by, followed by, or that include the words &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;believe,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or similar expressions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Forward-looking statements are inherently subject to risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not even
anticipate. Although we believe that the expectations reflected in the forward-looking statements are based upon reasonable assumptions at the time made, we can give no assurance that the expectations will be achieved. Future events and actual
results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The factors described under &#147;Risk Factors&#148; in this prospectus supplement and in any documents incorporated by reference herein and other factors could cause
our or our industry&#146;s future results to differ materially from historical results or those anticipated or expressed in any of our forward-looking statements. We operate in a continually changing business environment, and new risk factors emerge
from time to time. Other unknown or unpredictable factors also could have material adverse effects on our future results, performance or achievements. We cannot assure you that projected results or events will be achieved or will occur. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein completely and with the
understanding that our actual future results may be materially different from what we expect. Any forward-looking statement speaks only as of the date of this prospectus supplement. We do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may issue and sell shares of our common stock having aggregate gross sales proceeds of up to $250,000,000 from time to time. Because there is no minimum offering
amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. We currently intend to use the net proceeds from this
offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of businesses,
products and technologies or for other strategic purposes. The precise amount and timing of the application of such proceeds will depend upon our funding requirements and the availability and cost of other capital. As of the date of this prospectus
supplement, we cannot specify with certainty all of the particular uses for the net proceeds that we will have from the sale of the shares of our common stock. Pending these uses of the net proceeds from this offering, if any, we may invest the net
proceeds in investment grade, short-term interest-bearing obligations, such as money-market funds, certificates of deposit, or direct or guaranteed obligations of the United States government, or hold the net proceeds as cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_6"></A><A NAME="suptoc80466_6"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share
and the net tangible book value per share of our common stock after this offering. We calculate net tangible book value per share by dividing our net tangible assets (tangible assets less total liabilities) by the number of shares of our common
stock issued and outstanding as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our historical net tangible book value at June&nbsp;30, 2020 was $476,796,947 or approximately $4.66 per
share of our common stock. After giving effect to the sale of our common stock in the aggregate amount of $250,000,000 in this offering, at an assumed offering price of $44.12 per share, the last reported sale price of our common stock on Nasdaq on
August&nbsp;4, 2020, and after deducting estimated offering expenses and commissions payable by us, our adjusted net tangible book value as of June&nbsp;30, 2020 would have been approximately $720,471,697, or approximately $6.68&nbsp;per share of
our common stock. This represents an immediate increase in the net tangible book value of $2.01 per share of our common stock to our existing stockholders and an immediate dilution in net tangible book value of approximately $37.44 per share of our
common stock to new investors. The following table illustrates per share dilution: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net tangible book value per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjusted net tangible book value per share as of June&nbsp;30, 2020, after giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes for illustrative purposes that an aggregate of 5,666,364 shares of our common stock are sold at a price of
$44.12 per share, the last reported sale price of our common stock on Nasdaq on August&nbsp;4, 2020, for aggregate gross proceeds of $250,000,000. The shares sold in this offering, if any, will be sold from time to time at various prices. An
increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $44.12 per share shown in the table above, assuming all of our common stock in the aggregate amount of $250,000,000 is sold at that price, would
increase our adjusted net tangible book value per share after the offering by $0.008&nbsp;per share and would increase the dilution in net tangible book value per share to new investors in this offering to $38.44&nbsp;per share, after deducting
estimated offering expenses and commissions payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $44.12 per share shown in the table above, assuming all of our common stock in the
aggregate amount of $250,000,000 is sold at that price, would decrease our adjusted net tangible book value per share after the offering by $0.008&nbsp;per share and would decrease the dilution in net tangible book value per share to new investors
in this offering to $36.45&nbsp;per share, after deducting estimated offering expenses and commissions payable by us. This information is supplied for illustrative purposes only. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless we indicate otherwise, all information in this prospectus supplement is based on 102,250,872 shares of our common stock outstanding as of June&nbsp;30, 2020, and
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,529,564 shares of our common stock subject to options outstanding as of June 30, 2020 having a weighted average exercise
price of $15.71 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">3,327,075 restricted stock units granted and outstanding as of June 30, 2020 under our 2013 Equity Incentive Plan and
issued as inducement grants to new employees outside of our equity compensation plans. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that outstanding options are exercised, or we issue other shares, investors purchasing shares in this
offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of those securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into a Sales Agreement with Jefferies, under which we may offer and sell up to $250,000,000 of our shares of common stock from time to time through
Jefferies acting as agent. Sales of our shares of common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed to be an &#147;at the market offering&#148; as defined in Rule
415(a)(4) under the Securities Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each time we wish to issue and sell shares of common stock under the Sales Agreement, we will notify Jefferies of the number of
shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless
Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The
obligations of Jefferies under the Sales Agreement to sell our shares of common stock are subject to a number of conditions that we must meet. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The settlement of
sales of shares between us and Jefferies is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled
through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will pay Jefferies a commission of up to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum
offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Jefferies for the fees and
disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $50,000. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the
terms of the Sales Agreement, will be approximately $210,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies will provide written confirmation to us before the open on Nasdaq on the day following each day on which our shares of common stock are sold under the Sales
Agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection
with the sale of our shares of common stock on our behalf, Jefferies will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or
discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering of our shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i)&nbsp;the sale of all shares of common stock subject to
the Sales Agreement and (ii)&nbsp;the termination of the Sales Agreement as permitted therein. We and Jefferies may each terminate the Sales Agreement at any time upon prior notice. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement is
filed as an exhibit to our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed under the Exchange Act and incorporated by reference in this prospectus supplement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our
affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any
time hold long or short positions in such securities. For example, Jefferies acted as an underwriter in our public offering consummated in December 2019, for which it received compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website
maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of common stock offered hereby will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher, LLP, San Francisco, California.
Latham&nbsp;&amp; Watkins LLP, San Diego, California is counsel to Jefferies in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_9"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial
statements of the Company incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended September&nbsp;30, 2019 have been audited by Rose, Snyder&nbsp;&amp;
Jacobs, LLP as stated in their report incorporated by reference in this prospectus and elsewhere in this registration statement, and given upon the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_10"></A><A NAME="suptoc80466_10"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the
SEC&#146;s web site at http://www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We make available free of charge on or through our Internet website www.arrowheadpharma.com, our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form 8&#150;K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the
Exchange Act as soon as reasonably practicable after we electronically file the material with, or furnish it to, the SEC. The references to www.arrowheadpharma.com in this prospectus supplement, the accompanying prospectus and the documents
incorporated by reference herein or therein are inactive textual references only, and the information found on our internet website is not incorporated by reference into, and should not be considered part of, this prospectus supplement, the
accompanying base shelf prospectus or the documents incorporated by reference herein or therein. Investors should not rely on any such information in deciding whether to invest in our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc80466_11"></A><A NAME="suptoc80466_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC allows us to incorporate by reference information contained in documents we file with it, which means that we can disclose important information to you by
referring you to those documents already on file with the SEC that contain that information. The information incorporated by reference is considered to be part of this prospectus supplement, and later information that we file with the SEC will
automatically update and supersede this information. We incorporate by reference the documents listed below and any future information filed (rather than furnished) with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, between
the date of this prospectus supplement and the termination of the offering of the securities covered by this prospectus supplement, provided, however, that we are not incorporating any information furnished under any of Item 2.02 or Item 7.01 of any
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (and exhibits filed on such form that are related to such items): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Company&#146;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-10k_20190930.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended September&nbsp;30, 2019, filed on November&nbsp;
25, 2019 and the Company&#146;s Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000156459020003465/arwr-10q_20191231.htm">February&nbsp;5,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000156459020022860/arwr-10q_20200331.htm">May&nbsp;
7, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000156459020036812/arwr-10q_20200630.htm">August&nbsp;5, 2020</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Company&#146;s Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312520017001/d864868ddef14a.htm">Schedule
 14A</A>, filed on January&nbsp;28, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Company&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000156459019044001/arwr-8k_20191115.htm">November&nbsp;21,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312519308250/d831463d8k.htm">December&nbsp;6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312519316457/d851584d8k.htm">December&nbsp;
18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000156459020011831/arwr-8k_20200314.htm">March&nbsp;
19, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000156459020020542/arwr-8k_20200501.htm">May&nbsp;1, 2020</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The description of the Company&#146;s common stock contained in its registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312516533989/d131257d8a12ga.htm">Form
 <FONT STYLE="white-space:nowrap">8-A/A</FONT></A> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;000-21898),</FONT> filed on April&nbsp;7, 2016, including any amendments or reports filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon written or oral request, we will provide at no cost to the requester a copy of all of the information that has been incorporated by
reference in this prospectus supplement but not delivered with this prospectus supplement. You may obtain copies of these documents from us, without charge (other than exhibits, unless the exhibits are specifically incorporated by reference), by
contacting our Corporate Secretary, 177 E. Colorado Blvd., Suite 700, Pasadena, California 91105. Our telephone number is (626) <FONT STYLE="white-space:nowrap">304-3400.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may also access the documents incorporated by reference in this prospectus supplement through our website at www.arrowheadpharma.com. Except for the specific
incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus supplement or the registration statement of which it forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we or any selling stockholder may offer common stock, preferred stock, debt securities, warrants or a combination of any of these securities. The debt securities that we may offer may consist of senior debt securities or subordinated debt
securities, in each case consisting of notes or other evidence of indebtedness in one or more series. The warrants that we may offer may consist of warrants to purchase any of the other securities that may be sold under this prospectus. The
securities offered under this prospectus may be offered separately, together or in series separate, and in amounts, at prices and on terms to be determined at the time of sale. A prospectus supplement that will set forth the terms of the offering of
any securities will accompany this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer these securities through agents, underwriters or
dealers or directly to investors. See &#147;Plan of Distribution&#148; in this prospectus. Each prospectus supplement will provide the amount, price and terms of the plan of distribution relating to the securities to be sold pursuant to such
prospectus supplement. We will set forth the names of any underwriters or agents in the accompanying prospectus supplement, as well as the net proceeds we expect to receive from any such sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any accompanying prospectus supplement and the documents incorporated by reference in this prospectus and any
such prospectus supplement carefully before you invest. This prospectus may not be used to offer or sell any of the common stock, preferred stock, debt securities or warrants unless accompanied by a prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#147;ARWR.&#148; On November&nbsp;29, 2019, the closing sale
price of our common stock on The Nasdaq Global Select Market was $73.01 per share. Our principal executive offices are located at 177 E. Colorado Blvd, Suite 700, Pasadena, California 91105, and our telephone number is (626) <FONT
STYLE="white-space:nowrap">304-3400.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing in our
securities involves a high degree of risk. You should carefully consider the risk and uncertainties referenced under the heading &#147;<A HREF="#tx80466_4">Risk Factors</A>&#148; beginning on page 4 of this prospectus as well as those contained in
the applicable prospectus supplement and any related free writing prospectus, and in the other documents that are incorporated by referenced into this prospectus or any accompanying prospectus supplement. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is December&nbsp;2, 2019 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_6">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx80466_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">20</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized anyone to provide you with information in addition to
or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the reliability of, any information not contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in
jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document (unless
the information specifically indicates that another date applies) and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus,
any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission (the
&#147;SEC&#148;), as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Under this shelf registration process, we and/or selling stockholders may offer
common stock, preferred stock, debt securities or warrants over time in one or more offerings at prices and on terms to be determined by market conditions at the time of the offering. This prospectus only provides you with a general description of
the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders sell any common stock, preferred stock, debt securities or warrants under this prospectus, we will provide a prospectus supplement that will contain
more specific information about the securities being offered and the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. Each
prospectus supplement and any relating free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. If
there is any inconsistency between the information in this prospectus and any accompanying prospectus supplement or related free writing prospectus, you should rely on the information in the prospectus supplement or any related free writing
prospectus we may authorize to be provided to you. This prospectus may not be used to sell any common stock, preferred stock, debt securities or warrants unless accompanied by a prospectus supplement. You should carefully read this prospectus, any
applicable prospectus supplement and any related free writing prospectus, together with the additional information incorporated herein by reference as described under the headings &#147;Where You Can Find More Information&#148; and
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus, before you invest in any of the securities being offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148;<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus (including the documents incorporated by reference herein) contains certain forward-looking statements within the meaning of
federal securities laws, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this prospectus or any document incorporated by reference herein, except for
historical information, may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;believe,&#148; &#147;anticipate,&#148;
&#147;intend,&#148; &#147;could,&#148; &#147;estimate,&#148; or &#147;continue&#148; or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to
projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included herein are based on current expectations of our management based on available information and involve
a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking
statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1 (Business) and Item 1A (Risk Factors) of Part I and Item 7 (Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations) of Part II of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> factors
described under the section entitled &#147;Risk Factors&#148; in this prospectus, as may be updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and elsewhere in the
documents incorporated by reference in this prospectus. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the SEC. In light of the significant risks and
uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to
place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_3"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise noted, (1)&nbsp;the term &#147;Arrowhead&#148; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its
Subsidiaries, (2)&nbsp;the terms &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our,&#148; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or its Subsidiaries,
(3)&nbsp;the term &#147;Subsidiaries&#148; refers collectively to Arrowhead Madison Inc. (&#147;Arrowhead Madison&#148;), Arrowhead Australia Pty Ltd (&#147;Arrowhead Australia&#148;) and Ablaris Therapeutics, Inc. (&#147;Ablaris&#148;), (4) the
term &#147;Common Stock&#148; refers to Arrowhead&#146;s common stock, par value $0.001 per share, (5)&nbsp;the term &#147;Preferred Stock&#148; refers to Arrowhead&#146;s preferred stock, par value $0.001 per share and (6)&nbsp;the term
&#147;Stockholder(s)&#148; refers to the holders of Arrowhead common stock. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arrowhead Pharmaceuticals, Inc. develops medicines that
treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of
target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in
life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead&#146;s RNAi-based therapeutics leverage this natural pathway of gene silencing. Arrowhead is focused on
developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address
conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and
our pipeline now includes disease targets in the liver, lung, and solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 177 E.
Colorado Blvd., Suite 700, Pasadena, CA 91105 and our telephone number is (626) <FONT STYLE="white-space:nowrap">304-3400.</FONT> Additional information regarding our company, including our audited financial statements and descriptions of our
business, is contained in the documents incorporated by reference in this prospectus. See &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks
described in the sections entitled &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and subsequent Quarterly Reports on form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as filed with
the SEC, which are incorporated herein by reference in their entirety, as well any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including the applicable prospectus supplement. Our business, financial
condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the
incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the
risks mentioned elsewhere in this prospectus. For more information, see the section entitled &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds we receive from the sale of securities by us as set forth in the applicable prospectus supplement. Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_6"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Capital Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of our common stock and our preferred stock. You should refer to our Amended and Restated Certificate of
Incorporation (the &#147;Certificate of Incorporation&#148;) and our Amended and Restated Bylaws (the &#147;Bylaws&#148;), which are incorporated by reference into this prospectus. Copies of our Certificate of Incorporation and Bylaws may be
obtained as described under the heading &#147;Where You Can Find More Information&#148; in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up
to 145,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of November&nbsp;20, 2019, 95,708,027 shares of our common stock were issued and outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares
of our common stock from time to time. Holders of our common stock are entitled to one vote for each share held on each matter to be voted on by stockholders. There is no cumulative voting in the election of directors. The holders of our common
stock have no preemptive or conversion rights and are not subject to further calls or assessments. There are no redemption or sinking fund provisions applicable to our common stock. The rights of the holders of the our common stock are subject to
any rights that may be fixed for holders of preferred stock, if any. Holders of our common stock are entitled to receive ratably dividends out of funds legally available, if and when declared from time to time by our board of directors. In the event
of liquidation, dissolution or winding up of the affairs of the Company, holders of our common stock are to share in all assets remaining after the payment of liabilities and any preferential distributions payable to preferred stockholders, if any.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ARWR&#148;. The transfer agent and registrar for our
common stock is Computershare Trust Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of
directors has the authority, without further action by stockholders, to designate up to 5,000,000 shares of preferred stock, $0.001 par value per share, in one or more series and to fix the rights, preferences, privileges, qualifications and
restrictions granted to or imposed upon the preferred stock, including but not limited to dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be
greater than the rights of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications
and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designations relating to that series. If we issue preferred stock, we will incorporate by reference
into the registration statement of which this prospectus is a part the form of any certificate of designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We
urge you to read the prospectus supplement related to any series of preferred stock we may offer, as well as the complete certificate of designations that contains the terms of the applicable series of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). Section&nbsp;203 of the DGCL generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with an
&#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do
not have the right to determine whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP STYLE="font-size:85%; vertical-align:top"> 2</SUP>/3% of the outstanding voting stock that is not owned by the interested
stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets
of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Debt Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities under an indenture to be entered into between us and a trustee chosen by us, qualified to act as such under the
Trust Indenture Act of 1939, as amended (the &#147;Trust Indenture Act&#148;) and appointed under an indenture. The indenture will be governed by the Trust Indenture Act. The paragraphs below describe the general terms and provisions of the debt
securities we may issue. When we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants
relating to such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the indenture. It does not restate the indenture
entirely. We urge you to read the indenture. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and we will file the indenture we enter into and the supplemental indentures or
authorizing resolutions with respect to particular series of debt securities as exhibits to current or other reports we file with the SEC. See &#147;Where You Can Find More Information&#148; for information on how to obtain copies of the indentures
and the supplemental indentures or authorizing resolutions. You may also inspect copies of the documents for the particular series at the office of the trustee. References below to an &#147;indenture&#148; are references to the applicable indenture,
as supplemented, under which a particular series of debt securities is issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms of the Debt Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our debt securities will be general obligations of Arrowhead. We may issue them in one or more series. Authorizing resolutions or a
supplemental indenture will set forth the specific terms of each series of debt securities. We will provide a prospectus supplement for each series of debt securities that will describe: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether the debt securities are senior, senior subordinated, or subordinated
debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities and any limit upon the aggregate principal amount of the
series of debt securities, and, if the series is to be issued at a discount from its face amount, the method of computing the accretion of such discount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the percentage of the principal amount at which debt securities will be issued and, if other than the full
principal amount thereof, the percentage of the principal amount of the debt securities that is payable if maturity of the debt securities is accelerated because of a default; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which principal of the debt securities will be payable and the amount of principal that will
be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) at which the debt securities will bear interest, if any, or
the method of calculation of such rate or rates, as well as the dates from which interest will accrue, the dates on which interest will be payable and the record date for the interest payable on any payment date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any collateral securing the performance of our obligations under the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies (including any composite currency) in which principal, premium, if any, and interest,
if any, will be payable, and if such payments may be made in a currency other than that in which the debt securities are denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between
the currency in which such securities are denominated and the currency in which such securities or any of them may be paid, and any additions to, modifications of or deletions from the terms of the debt securities to provide for or to facilitate the
issuance of debt securities denominated or payable in a currency other than U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal, premium, if any, and interest, if any, on the debt securities will be
payable and where debt securities that are in registered form can be presented for registration of transfer or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issuable, if different from $2,000 and multiples of $1,000
in excess thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions regarding our right to redeem or purchase debt securities or the right of holders to require us to
redeem or purchase debt securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right, if any, of holders of the debt securities to convert or exchange them into our common stock or other
securities of any kind of us or another obligor, including any provisions intended to prevent dilution of the conversion rights and, if so, the terms and conditions upon which such securities will be so convertible or exchangeable, including the
initial conversion or exchange price or rate or the method of calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at our option, the conversion
or exchange period, and any other provision in relation thereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions requiring or permitting us to make payments to a sinking fund to be used to redeem debt securities
or a purchase fund to be used to purchase debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms, if any, upon which debt securities may be senior or subordinated to our other indebtedness;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additions to, modifications of or deletions from the terms of the debt securities with respect to events of
default or covenants or other provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and upon what terms the debt securities of such series may be defeased or discharged, if different from
the provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in registered or bearer form and the terms of these forms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in whole or in part in the form of a global security and, if
applicable, the identity of the depositary for such global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provision for electronic issuance of the debt securities or issuance of the debt securities in uncertificated
form; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities, which may be different from the terms set forth in this
prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will also describe any material covenants to which a series of debt
securities will be subject and the applicability of those covenants to any of our subsidiaries to be restricted thereby, which are referred to herein as &#147;restricted subsidiaries.&#148; The applicable prospectus supplement will also describe
provisions for restricted subsidiaries to cease to be restricted by those covenants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default and Remedies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, an event of default with respect to any series of debt securities will be
defined in the indenture or applicable supplemental indenture or authorizing resolution as being: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay interest on any debt security of such series when the same becomes due and payable and the
continuance of any such failure for a period of 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay the principal or premium of any debt security of such series when the same becomes due and
payable at maturity, upon acceleration, redemption or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure or the failure of any restricted subsidiary to comply with any of its agreements or covenants in, or
provisions of, the debt securities of such series or the indenture (as they relate thereto) and such failure continues for a period of 60 days after our receipt of notice of the default from the trustee or from the holders of at least 25% in
aggregate principal amount of the then outstanding debt securities of that series (except in the case of a default with respect to the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or other disposition of
all or substantially all of the assets of us (or any other provision specified in the applicable supplemental indenture or authorizing resolution), which will constitute an event of default with notice but without passage of time);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default under any mortgage, indenture or instrument under which there may be issued or by which there may be
secured or evidenced any indebtedness (other than <FONT STYLE="white-space:nowrap">non-recourse</FONT> indebtedness, as defined in the indenture) for money borrowed by us or any of our restricted subsidiaries (or the payment of which is guaranteed
by us or any of our restricted subsidiaries), whether such indebtedness or guarantee now exists or is created after the date we issue debt securities, if that default: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is caused by a failure to pay at final stated maturity the principal amount of such indebtedness prior to the
expiration of the grace period provided in such indebtedness on the date of such default (a &#147;Payment Default&#148;); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">results in the acceleration of such indebtedness prior to its express maturity without such indebtedness having
been discharged or such acceleration having been cured, waived, rescinded or annulled for the period and after the notice had been provided, and, in each case, the principal amount of any such indebtedness, together with the principal amount of any
other such indebtedness under which there has been a Payment Default or the maturity of which has been so accelerated, aggregates $50&nbsp;million or more; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy, insolvency or reorganization occur with respect to us or any restricted subsidiary
that is a significant subsidiary (as defined in the indenture). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that the trustee may
withhold notice to the holders of any series of debt securities of any default, except a default in payment of principal or interest, if any, with respect to such series of debt securities, if the trustee considers it in the interest of the holders
of such series of debt securities to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that if any event of default has occurred and is continuing with
respect to any series of debt securities, the trustee or the holders of not less than 25% in principal amount of such series of debt securities then outstanding may declare the principal of all the debt securities of such series to be due and
payable immediately. However, the holders of a majority in principal amount of the debt securities of such series then outstanding by notice to the trustee may waive any existing default and its consequences with respect to such series of debt
securities, other than any event of default in payment of principal or interest. Holders of a majority in principal amount of the then outstanding debt securities of any series may rescind an acceleration with respect to such series and its
consequences, except an acceleration due to nonpayment of principal or interest on such series, if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to such series have been cured or
waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the outstanding principal amount of the debt securities of any series will have the right to direct
the time, method and place of conducting any proceedings for any remedy available to the trustee with respect to such series, subject to limitations specified in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Defeasance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will
permit us to terminate all our respective obligations under the indenture as they relate to any particular series of debt securities, other than the obligation to pay interest, if any, on and the principal of the debt securities of such series and
certain other obligations, at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been
the case otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will also permit us to terminate all of our respective obligations under the
indenture as they relate to any particular series of debt securities, including the obligations to pay interest, if any, on and the principal of the debt securities of such series and certain other obligations, at any time by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
(A)&nbsp;we have received from, or there has been published by, the Internal Revenue Service a ruling, or (B)&nbsp;since the date such series of debt securities were originally issued, there has been a change in the applicable federal income tax
law, in either case to the effect that, and based thereon such opinion of counsel shall state that, holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to
federal income tax on the same amount and in the same manner and at the same times as would have been the case otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the indenture will permit us to terminate substantially all our respective
obligations under the indenture as they relate to a particular series of debt securities by depositing with the trustee money or government obligations sufficient to pay all principal and interest on such series at its maturity or redemption date if
the debt securities of such series will become due and payable at maturity within one year or are to be called for redemption within one year of the deposit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer and Exchange </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder
will be able to transfer or exchange debt securities only in accordance with the indenture. The registrar may require a holder, among other things, to furnish appropriate endorsements and transfer documents, and to pay any taxes and fees required by
law or permitted by the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment, Supplement and Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without notice to or the consent of any holder, we and the trustee may amend or supplement the indenture or the debt securities of a series to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cure any ambiguity, omission, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or other
disposition of all or substantially all of our assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that specific provisions of the indenture shall not apply to a series of debt securities not previously
issued or to make a change to specific provisions of the indenture that only applies to any series of debt securities not previously issued or to additional debt securities of a series not previously issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create a series and establish its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add a guarantor subsidiary in respect of any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the
Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that does not adversely affect the rights of any holder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conform the provisions of the indenture to the final offering document in respect of any series of debt
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exceptions discussed below, we and the trustee may amend or supplement the indenture or the debt
securities of a particular series with the written consent of the holders of at least a majority in principal amount of the debt securities of such series then outstanding. In addition, the holders of a majority in principal amount of the debt
securities of such series then outstanding may waive any existing default under, or compliance with, any provision of the debt securities of a particular series or of the indenture relating to a particular series of debt securities, other than any
event of default in payment of interest or principal. These consents and waivers may be obtained in connection with a purchase of, or tender offer or exchange offer for, debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without the consent of each holder affected, we and the trustee may not: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities of such series whose holders must consent to an amendment, supplement or
waiver; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest, including defaulted interest;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or extend the fixed maturity of any debt security or alter the provisions with respect to
redemptions or mandatory offers to repurchase debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that adversely affects any right of a holder to convert or exchange any debt security into or for
shares of our common stock or other securities, cash or other property in accordance with the terms of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the ranking or priority of the debt securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to any provision of the indenture relating to the waiver of existing defaults, the rights of
holders to receive payment of principal and interest on the debt securities, or to the provisions regarding amending or supplementing the indenture or the debt securities of a particular series with the written consent of the holders of such series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a continuing default or event of default in the payment of principal of or interest on the debt securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any debt security payable at a place or in money other than that stated in the debt security, or impair the
right of any holder of a debt security to bring suit as permitted by the indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of any holder to
participate in any consent required or sought pursuant to any provision of the indenture, and our obligation to obtain any such consent otherwise required from such holder, may be subject to the requirement that such holder shall have been the
holder of record of debt securities with respect to which such consent is required or sought as of a record date fixed by us in accordance with the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concerning the Trustee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture will contain limitations on the rights of the trustee, should it become our creditor, to obtain payment of claims in specified cases or to realize on property received in respect of any such claim as security or otherwise. The indenture
will permit the trustee to engage in other transactions; however, if it acquires any conflicting interest, it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that in case an event of default occurs and is not cured, the trustee will be required, in the exercise of its
power, to use the degree of care of a prudent person in similar circumstances in the conduct of such person&#146;s own affairs. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the indenture at the
request or direction of any of the holders pursuant to the Indenture, unless such holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be incurred by it
in compliance with such request or direction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Recourse against Others </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that a director, officer, employee or stockholder, as such, of the Company shall not have any liability for any
obligations of the Company under the debt securities or the indenture or for any claim based on, in respect of or by reason of, such obligations or their creation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of the
State of New York will govern the indenture and the debt securities. <B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Description of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of debt securities, common stock, preferred stock or any combination of these securities. Warrants may
be issued independently or together with other securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between a warrant agent and us.
The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. The following outlines some of the general
terms and provisions of the warrants that we may issue from time to time. Additional terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement. The following description, and any description
of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions of the applicable warrant agreement, which we will file with the SEC in connection with
any offering of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular issue of warrants exercisable for debt securities will describe the terms of those warrants,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the debt securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities that the warrants are issued with and the number of
warrants issued with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and any securities issued with the warrants will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount and price of debt securities that may be purchased upon exercise of a warrant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants commences and expires; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants represented by the warrant certificates or debt securities that may be issued upon exercise
of the warrants will be issued in registered or bearer form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information relating to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anti-dilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption or call provisions, if any, applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular issue of warrants exercisable for common stock or preferred stock will describe the terms of
the common stock warrants and preferred stock warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities that the warrants are issued with and the number of
warrants issued with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and any securities issued with the warrants will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and price of common stock or preferred stock that may be purchased upon exercise of a
warrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants commences and expires; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anti-dilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption or call provisions, if any, applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the
principal amount of debt securities or shares of common stock or preferred stock being offered. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the
close of business on the expiration date, unexercised warrants will be void. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered. Until a holder exercises the warrants to purchase any
securities underlying the warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledgees, donees or successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus, any applicable prospectus supplement or post-effective
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding the beneficial ownership of our securities by a selling stockholder, the number of securities being
offered by a selling stockholder and the number of securities beneficially owned by a selling stockholder after the applicable offering, where applicable, will be set forth in a prospectus supplement or in a post-effective amendment. The applicable
prospectus supplement or post-effective amendment will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise has had a material relationship with us during the three years prior
to the date of the applicable prospectus supplement, or post-effective amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered by this prospectus from time to time in any manner permitted under the Securities Act. Registration of the
securities covered by this prospectus does not mean, however, that those securities will necessarily be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the
securities separately or together: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwriters or dealers in a public offering and sale by them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to dealers; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also make direct sales through subscription rights distributed to our stockholders on a pro rata basis, which may or may not be
transferable. In any distribution of subscription rights to stockholders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more
underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the
securities from time to time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in one or more transactions at a fixed price or prices, which may be changed from time to time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the prices may represent a discount from prevailing market prices. We will describe the method of distribution of the securities and
the terms of the offering in the applicable prospectus supplement. Any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be
resold from time to time in one or more of the transactions described above. Any underwritten offering may be on a best efforts or firm commitment basis. The securities may be either offered to the public through underwriting syndicates represented
by managing underwriters, or directly by underwriters. Generally, the underwriters&#146; obligations to purchase the securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the securities if they
purchase any of the securities. We may use underwriters with whom we have a material relationship. We will describe in the applicable prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any sale of the securities, underwriters or agents may receive compensation from us or from purchasers of the securities, for whom they may
act as agents, in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
and/or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities may be deemed to be underwriters under the Securities Act, and any discounts or
commissions they receive from us and any profit on the resale of securities they realize may be deemed to be underwriting discounts and commissions under the Securities Act. Any initial public offering price and any discounts or concessions allowed
or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may be changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities,
we will describe the method of distribution of the securities in the applicable prospectus supplement relating to such transaction. The applicable prospectus supplement will, where applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify any such underwriter or agent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">describe any compensation in the form of discounts, concessions, commissions or otherwise received from us by
each such underwriter or agent and in the aggregate to all underwriters and agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify the amounts underwritten or to be sold through the agent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify the nature of the underwriter&#146;s or agent&#146;s obligation to take the securities.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to
purchase the securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to
those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale
transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those
derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the underwriters, dealers and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover
over-allotments, if any, in connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the related prospectus supplement, all
securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at
any time without notice. Any common stock sold pursuant to a prospectus supplement will be listed for trading on The Nasdaq Global Select Market or other principal market for our common stock. We may apply to list any series of debt securities,
preferred stock or warrants on an exchange, but we are not obligated to do so. Therefore, there may not be liquidity or a trading market for any series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment transactions, stabilizing transactions, short-covering transactions and penalty bids in
accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling
concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If
commenced, the underwriters may discontinue any of the activities at any time. We make no representation or prediction as to the direction or magnitude of any effect that such transactions may have on the price of the securities. For a description
of these activities, see the information under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148; in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents who may become involved in the sale of the common stock may engage in transactions with and perform
other services for us in the ordinary course of their business for which they receive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply with applicable state
securities laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through registered or licensed brokers or dealers. In addition, securities may not be sold in some states unless they have been
registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of the Company incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended September&nbsp;30, 2019 have been audited by Rose, Snyder&nbsp;&amp; Jacobs, LLP as stated in their report incorporated by reference in this prospectus and elsewhere in this registration
statement, and given upon the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_10"></A>LEGAL MATTERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the issuance of the securities being offered hereby and the binding nature of any debt securities or warrants being
offered hereby is being passed upon by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California. The legality of the securities will be passed upon by counsel for any underwriters, dealers or agents as may be specified in the applicable
prospectus supplement.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must comply with the informational requirements of the Exchange Act, and we are required to file reports and proxy statements and other
information with the SEC. This prospectus, which forms part of the registration statement, does not contain all of the information included in the registration statement, including its exhibits and schedules. For further information about us and the
securities described in this prospectus, you should refer to the registration statement, its exhibits and schedules and our reports, proxies, information statements and other information filed with the SEC. Our filings are available to the public on
the Internet, through a database maintained by the SEC at <I>http://www.sec.gov</I>. Our filings are also available, free of charge, on our website at <I>www.arrowheadpharma.com</I>. The information contained in, or that can be accessed through, our
website is not incorporated by reference herein and is not part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus as to the
contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects
by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx80466_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference in this prospectus the information that we file with it. Incorporation by reference means that
we can disclose important information to you by referring you to other documents that are legally considered to be part of this prospectus. Later information that we file with the SEC will automatically update and supersede the information in this
prospectus, any supplement and the documents listed below. Our SEC file number is <FONT STYLE="white-space:nowrap">0-21898.</FONT> We incorporate by reference the specific documents listed below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-10k_20190930.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended September&nbsp;30, 2019, filed on November&nbsp;25, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312519017078/d687022ddef14a.htm">Definitive
 Proxy Statement on Schedule 14A</A>, filed on January&nbsp;25, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000156459019044001/arwr-8k_20191115.htm">Form
 8-K</A> filed on November 21, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of the Company&#146;s Common Stock contained in its registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/879407/000119312510242705/d8a12ga.htm">Form
 <FONT STYLE="white-space:nowrap">8-A/A</FONT></A> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;000-21898),</FONT> filed on November&nbsp;1, 2010, including any amendments or reports filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any
portion of any report or documents that is not deemed filed under such provisions on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement
of which this prospectus is a part has been withdrawn, shall be deemed incorporate </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this prospectus shall be deemed to
incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral request, we will furnish without charge to each person, including any beneficial owner, to whom this prospectus is
delivered, upon written or oral request, a copy of any document incorporated by reference. Requests should be addressed to Corporate Secretary, 177 E Colorado Blvd., Suite 700, Pasadena, California 91105 or may be made telephonically at (626) <FONT
STYLE="white-space:nowrap">304-3400.</FONT> We have not authorized anyone to provide you with different information. You should not assume that the information contained in this prospectus or the accompanying prospectus supplement is accurate on any
date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any
accompanying prospectus supplement is delivered or securities are sold on a later date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80466g58w64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Up to $250,000,000 </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">August&nbsp;5, 2020 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g80466g58w64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80466g58w64.jpg
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M,D)WM+<E,U%76'67-#E#1%)368&5EM76U[7_Q  = 0 !! ,! 0
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M\OZ!Q)H_K5/_ 'J?OPROI._L+:D_WILK_$NV=-T/U9/B_P#G.'LS^N2_"/\
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MJ6%!(>\F.H#?8[FQ)L#8 CI=CMMN1'CIDK:EVA4PTXTEMMU\(NHW(N6#$;V
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M^[H+>"^'G->(:BMIN*P+2;U\6/C\6,S+"R@(R6S$):K\HU/AM.*K%FA6Q6I
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MHP9/EG/BAA.,=L=-T( IU(YLS$^I!(_<!A[-&)K'!.RJ@'H"H;]Y.++C QI
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MW[=K.U1Q@S49*&/U>5?96D2S5)\I[,%/QI&4X:)9,"PVDK#*UJ!DFC8TKVS
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M+=>=6XO.5*SGK:J""&E@AIJ:)(*>FBC@@AB4)'##"@CBBC06"I&BJB*!95
MV&-1:BHGJZB>JJ99)ZFIFEJ*B>5B\LT\SM)++([$L\DDC,[L22S$DFYQZ9F@
MSOJ>BM*R7?R^H:EUP=Y=\Y\OETZ&([]\_?/?W._?/WS^_KDMQ)'W/$6?16MW
M6=9I';RT5TZVVVZ8[&\+R=]PSP[-_6Y%E$GZ^7T[?QP[75+B]Q@[-9J_3("7
MM5KF(^O5N!!>DIJ;E26PXV+CQT^3YAI3N4M,#LI_,XXO.$IQ]\YZPS!068V
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MWQ"'H]40.\5*"D/9(^(F1CV!B%F1>",R+&6'D."I<;6G"#40ABIE0$7N-0Z
MDCXBQN.8MA8IJ@J'$,A5K6.@V-]@?@>AY>N%K([OT_$0=-LTKLJF1E=V&WAZ
MCSDA/@!Q-H8S'YEO?ASR'FQBF,1F%2"GDN>T@-*B%K2TG*L*,L8"DNH#^Z21
M8[7V/PP@0RDNHC<F/WQI-UWMN.F^P\SRPG8ODWQ]FJB!?HW;]$(I<I<VM=Q]
MG5/"#PQ=X?'^8Q6&32E,M*EGQ/YTR-W[NC9P0WE36<+S@31%0PD726T WVU6
MOI^-M_AA1IY@Q0Q.'"=X5TFX0?:(\L8F)Y<\8)R+MTU$[YU:=$T1IHBV'LV^
M(^-#C/E( &*<<60C!(A9[K( 18/R1S#GQPQ77B2&6EX$\)#$2I9?>.H6%^7Q
MN=MNNW/&32U"E089 7-E!0W)YD<N@W-^0WY8<K6VUM;;AKWXKU==JY>Z\DMV
M/=E*W)CR+ I["&W'0#4M*]X$YMIYE]0AC3!'L/L/^W[+[2UK21)!J1@PY7!Y
M'R/EAN2.2)M,B,C<[,"+CS'F/4;8;$CE_P 7!;!-U4C?NJF9ZN#R),U'KN,/
MC(2(=ETB6;41\GXCQ48RP0[(!#$/&!H&)R0PW\=[P1[1!<KWJ7%[^(=+W]+B
MQN.>'/9:C2K=S)I:VDZ#OJMIZ=;BQZX<R?VSK&JT039]FOM4@->2$?&2L?<9
M>; CX"0 FA6S89\"0)>;9,S+"NMO1K(RG7SD+3\9IW*L8Z69$50Y90A (8FP
M(.XM\1RPA8I&<QJC-("04 )8%>=P/+KY8Q^L]VZBW+$R$YJS8U1O49$N):ER
M*]-"&KB'%H<<;3+"X<27&>\VTZZQD]@=+[33CK.5MH4K DD<@)1U8#G8\NN_
ME\\$D,L1"R1LA.X#"U_AY_+"8I_*/CIL&XN:^I.Z];VBYH60VW7X:TQ9AQS@
MB5K*;B?;?RS,N#-MNNOHB735M,M.O.82VTXI*5GA=M"R(S>0(W^'0_*^%/3S
MH@=XI%0V\14@;\K^5_6V',!OM+DKC-Z^C[/"F7>M1L?,3]5'.9<FX>+EL)S&
M'R "59?&%.PI.1GG$X2[C/Y,YZ7J4L4!&H $KU /(X;*.$$A4A&)"M;8D<P#
MYCRPQVX^4.M:!I3<FSJY?:%)2.M&KQ4Q&I"6;(B,[FK=>.D8O7$N@,T,G,V5
M*- ADP@Y@DDX@GVF'6'EH<2U).B12NK*2@8 7V[P D(;;W)L+##\5-(\T4;(
MX$FAC86/=,P!D%QR N;V(\\,"QOQKD9Q2UCL2O<G:7Q]MQD_K-.Q+17 8N>B
M8JX2 (Y\QJ94=8IAU<8;)D2 WQQ2Y(N0_FHX1># S2VW6^][V!&$RQ-=-3*
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M104+&'AS,;<(F30\+%L"->9<;XANO83A[+#;2//Q:;PE^K1-$*:5"M41@J
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M,_ZH]8_^PJK_ /$]/?R@S[_;>;_[RK/];#'\G.'O]A9-_NNA_P!#!^A/3/\
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M=-]9WMRP_"XZ/<-9DG 0W)$9EP<>06,RLT=AW[NLLE*1E]IEW/W<;;<2A?\
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@C.=9PG!T8,'1@P=&#!T8,'1@P=&#!T8,'1@P=&#'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
